Thyrocare Technologies Limited has informed the Exchange about additional Capital infusion in Thyrocare Laboratories (Tanzania) Limited.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Thyrocare Technologies has invested an additional USD 175,000 (approximately INR 1.5 Crores) into its Tanzanian subsidiary, Thyrocare Laboratories (Tanzania) Limited, by subscribing to Compulsorily Convertible Irredeemable Preference Shares (CCPS). This is part of a broader plan approved by the Board to invest up to INR 15 Crores in the subsidiary in multiple tranches, of which INR 5.69 Crores (USD 675,020) has been deployed so far. Thyrocare Tanzania, a joint venture with the Kastipharm Group, is a subsidiary of the company with Thyrocare holding 57.25% equity. The newly operational subsidiary (started April 2024) reported a turnover of INR 1 Crore and a net worth of INR 2.09 Crores for FY25. The fresh capital is intended to support working capital and business operations of the Tanzania unit.
This is a routine, incremental capital infusion in an existing overseas subsidiary and is not expected to have a material impact on the stock. However, investors should note the ongoing build-out of Thyrocare's African footprint, with the total committed investment of up to INR 15 Crores still ahead of deployment in future tranches.